Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Jasper Therapeutics, Inc. (JSPR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0.58, with a market capitalisation of $21.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.32 to $2.69. This page covers its latest market performance, valuation, price trends and company information.
$21.06M | |
$0.58 | |
$188.80 | |
$0.32 | |
$0.57 | |
234.00 | |
1.42M | |
-- | |
$2.69 | |
$0.32 | |
-- | |
-- |
Jasper Therapeutics, Inc. (JSPR) is trading at $0.58 in pre-market trading as of 2026-09-16 08:01:00, up 2.09% ($0.01) from the previous close of $0.57
Pre-market trading shows how investors are pricing JSPR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Jasper Therapeutics, Inc. (JSPR) moved from $0.71 to $0.58, representing a decline of 17.87% ($0.13).
The stock traded between $0.57 and $0.74 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 284.68 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.2%
JSPR is currently trading at $0.58, placing it 11.2% of the way from its 52-week low of $0.32 to its 52-week high of $2.69. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Jasper Therapeutics, Inc. (JSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.